NANOPARTICLE-BASED DRUG DELIVERY SYSTEMS FOR TARGETED CANCER THERAPY: CURRENT ADVANCES AND CHALLENGES

Authors

  • Dr. Camille Laurent Department of Pharmaceutical Nanotechnology, European Institute of Biomedical Sciences, Paris, France

Keywords:

nanoparticles; targeted drug delivery; cancer nanomedicine; liposomes; active targeting; EPR effect; tumor microenvironment; stimuli-responsive systems; clinical translation.

Abstract

Nanoparticle-based drug delivery has become a central strategy for improving the therapeutic index of anticancer agents by modifying pharmacokinetics, protecting unstable payloads, enabling combination treatment, and creating opportunities for tumor-selective delivery. This structured narrative review evaluates current advances in lipid, polymeric, protein, inorganic, and biomimetic nanoparticles for targeted cancer therapy, with particular attention to passive accumulation, ligand-mediated active targeting, stimuli-responsive release, tumor penetration, clinical translation, and manufacturing constraints. The evidence indicates that nanocarriers can substantially alter drug exposure and reduce selected formulation-related toxicities, but tumor accumulation remains heterogeneous and frequently inefficient. The classical enhanced permeability and retention (EPR) model is therefore increasingly supplemented by mechanistic concepts involving active endothelial transport, stromal interactions, immune clearance, and patient-specific tumor biology. Active targeting improves receptor-mediated binding and internalization when particles have already reached tumor tissue, but it does not automatically solve the systemic delivery problem. Stimuli-responsive and multifunctional systems are promising for spatially and temporally controlled release, although their added complexity can complicate characterization, scale-up, and regulatory assessment. The most clinically mature platforms remain liposomes, lipid nanoparticles, albumin-based systems, and selected polymeric formulations. Future progress will depend on rational nanoparticle engineering, biomarker-guided patient selection, quantitative imaging of delivery, reproducible manufacturing, and early integration of translational and regulatory requirements.

 

 

References

1.Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017). Cancer nanomedicine: Progress, challenges and opportunities. Nature Reviews Cancer, 17(1), 20–37. https://doi.org/10.1038/nrc.2016.108

2.Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016). Analysis of nanoparticle delivery to tumours. Nature Reviews Materials, 1, 16014. https://doi.org/10.1038/natrevmats.2016.14

3.Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021). Engineering precision nanoparticles for drug delivery. Nature Reviews Drug Discovery, 20(2), 101–124. https://doi.org/10.1038/s41573-020-0090-8

4.Rosenblum, D., Joshi, N., Tao, W., Karp, J. M., & Peer, D. (2018). Progress and challenges towards targeted delivery of cancer therapeutics. Nature Communications, 9, 1410. https://doi.org/10.1038/s41467-018-03705-y

5.Blanco, E., Shen, H., & Ferrari, M. (2015). Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nature Biotechnology, 33(9), 941–951. https://doi.org/10.1038/nbt.3330

6.Zhang, P., Xiao, Y., Sun, X., Lin, X., Koo, S., Yaremenko, A. V., Qin, D., Kong, N., Farokhzad, O. C., & Tao, W. (2023). Cancer nanomedicine toward clinical translation: Obstacles, opportunities, and future prospects. Med, 4(3), 147–167. https://doi.org/10.1016/j.medj.2022.12.001

7.Anselmo, A. C., & Mitragotri, S. (2019). Nanoparticles in the clinic: An update. Bioengineering & Translational Medicine, 4(3), e10143. https://doi.org/10.1002/btm2.10143

8.Dutta, B., Barick, K. C., & Hassan, P. A. (2021). Recent advances in active targeting of nanomaterials for anticancer drug delivery. Advances in Colloid and Interface Science, 296, 102509. https://doi.org/10.1016/j.cis.2021.102509

9.Nguyen, L. N. M., Ngo, W., Lin, Z. P., Sindhwani, S., MacMillan, P., Mladjenovic, S. M., & Chan, W. C. W. (2024). The mechanisms of nanoparticle delivery to solid tumours. Nature Reviews Bioengineering, 2, 201–213. https://doi.org/10.1038/s44222-024-00154-9

10.He, H., Liu, L., Morin, E. E., Liu, M., & Schwendeman, A. (2019). Survey of clinical translation of cancer nanomedicines—Lessons learned from successes and failures. Accounts of Chemical Research, 52(9), 2445–2461.

11.Sun, D., Zhou, S., & Gao, W. (2020). What went wrong with anticancer nanomedicine design and how to make it right. ACS Nano, 14(10), 12281–12290.

12.van der Meel, R., Sulheim, E., Shi, Y., Kiessling, F., Mulder, W. J. M., & Lammers, T. (2019). Smart cancer nanomedicine. Nature Nanotechnology, 14, 1007–1017.

13.Golombek, S. K., May, J. N., Theek, B., Appold, L., Drude, N., Kiessling, F., & Lammers, T. (2018). Tumor targeting via EPR: Strategies to enhance patient responses. Advanced Drug Delivery Reviews, 130, 17–38.

14.Liu, Y., Zhang, Y., Li, H., & Hu, T. Y. (2025). Recent advances in the bench-to-bedside translation of cancer nanomedicines. Acta Pharmaceutica Sinica B, 15(1), 97–122. https://doi.org/10.1016/j.apsb.2024.12.007

15.Cheng, Z., Huang, H., Yin, M., & Liu, H. (2025). Applications of liposomes and lipid nanoparticles in cancer therapy: Current advances and prospects. Experimental Hematology & Oncology, 14, 11. https://doi.org/10.1186/s40164-025-00602-1

Published

2026-09-20